BTIG Maintains Buy on Glaukos, Raises Price Target to $205
BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $202 to $205.
Stocks · News reference
Glaukos Announces Topline Results From Its Phase 4 Trial Evaluating iDose TR With Cataract Surgery In Patients With Open-Angle Glaucoma Or Ocular Hypertension; Study Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority And Clinically Meaningful IOP Reduction Vs Cataract Surgery Alone
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
Glaukos reports positive three-year Epioxa study results and secures an exclusive license for RevOpsis retinal candidate RO-104.